Clinical Trials
2 trialsNCT06762327 2025-01-07
Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
Nanjing First Hospital, Nanjing Medical University
Phase 2 Not yet recruiting
NCT02959619 2023-08-21
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Betta Pharmaceuticals Co., Ltd.
Phase 1 Completed